SCHEMBL5740688

SCHEMBL5740688

CCC1CCc2c(sc3cc(-c4ccccn4)ccc3c2=O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.37
RAB9A P51151 1/20 0.37
TNIK Q9UKE5 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PI4KA P42356 1/20 0.36
PIK3CG P48736 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
METAP2 P50579 1/20 0.35
PDE5A O76074 4/20 0.35
PRMT5 O14744 2/20 0.35
WDR77 Q9BQA1 1/20 0.35
RORC P51449 1/20 0.34
HCRTR1 O43613 4/20 0.34
HCRTR2 O43614 4/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
PDE6C P51160 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5739050 0.89 KDM4E (0.39) NPC1KDM4EALDH1A1RAB9ATNIK
SCHEMBL5738978 0.85 TNIK (0.41) NPC1KDM4EALDH1A1RAB9ATNIK
SCHEMBL5739488 0.81 MAPT (0.38) NPC1KDM4EALDH1A1RAB9ATNIK
SCHEMBL5741786 0.81 PIK3CD (0.37) KDM4EALDH1A1RAB9ATNIKPIK3CD
SCHEMBL5741212 0.80 TNIK (0.37) NPC1KDM4EALDH1A1RAB9ATNIK
SCHEMBL5741298 0.80 BRD4 (0.39) NPC1KDM4EALDH1A1RAB9ATNIK
SCHEMBL5739961 0.80 KDM4E (0.34) NPC1KDM4EALDH1A1RAB9ATNIK
SCHEMBL5740790 0.79 PTPN5 (0.36) NPC1KDM4EALDH1A1RAB9ATNIK
SCHEMBL5741517 0.78 ALDH1A1 (0.34) NPC1KDM4EALDH1A1RAB9ATNIK
SCHEMBL5740778 0.78 MAPT (0.39) NPC1KDM4EALDH1A1RAB9ATNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406891-B1 THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES BAYER HEALTHCARE AG (DE) 2006-03-22 EP disclosed
US-20050009820-A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases BAYER HEALTHCARE AG (DE) 2005-01-13 US disclosed
EP-1406891-A1 THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES Bayer HealthCare AG (DE) 2004-04-14 EP disclosed
WO-2003053955-A1 THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES BAYER HEALTHCARE AG (DE) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009820-A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases HTT, HMOX1, SNCA NPC1 1078/4885KDM4E 2960/4885ALDH1A1 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.